Studies Keeping Coming on Roche’s Avastin; Latest Is Positive

February 25th, 2010 admin
Share/Save/Bookmark

Add To Delicious Digg This post Stumble this post
Topics: ,

We recounted earlier this week that Roche’s cancer drug Avastin had missed achieving its main target in a stomach-cancer study. Today the news is flipped as a new study reported Avastin showed positive results in the treatment of advanced ovarian cancer. The latest showed that women who continued using Avastin alone after receiving Avastin in combination with chemotherapy lived longer without the disease worsening, compared with those who received chemotherapy …


Originally posted on WSJ

 
  Related Posts
Medicare Chemo Payment Cuts: How Did They Affect Cancer Patients?
As a result of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, physician reimbursements for outpatient treatment of cancer patients were lowered. In the first study to examine how these reductions affected the likelihood and setting of chemotherapy treatments for Medicare beneficiaries, researchers looked at patients recently... 
Medicare cuts increase cancer treatments, study finds
The 2005 Medicare modernization act, which substantially reduced Medicare payments to physicians for administering outpatient chemotherapy drugs, has paradoxically increased, rather than decreased, chemotherapy treatment rates among Medicare recipients. [Original News Article] Related NewsDoctors Recouped Cuts in Medicare Pay, Study FindsReport: Cuts... 
Another FDA Advisory Panel Meeting: This Time, It’s Avastin
Another FDA Advisory Panel Meeting: This Time, It’s Avastin
What will the FDA’s oncology-drug panel recommend for Roche’s Avastin?  Read More →
Same-Sex Couples Face Inequities In Access To Health Coverage
Partnered gay men in California are only 42 percent as likely as married heterosexual men to get employer-sponsored dependent health insurance. Partnered lesbians in the state have an even smaller chance (28 percent) of getting that same coverage, compared to married heterosexual women. Those findings are contained in a Web First article released online... 
Pfizer Experimental Bone Drug Shows Mixed Results In Study
Pfizer Experimental Bone Drug Shows Mixed Results In Study
Last we heard of Fablyn, an experimental bone drug for the treatment of postmenopausal women, U.S. regulators were holding off on approval after FDA staff and outside reviewers raised concerns and Pfizer, the pill’s maker, was shopping it around to other companies. Today’s New England Journal of Medicine reports that the drug met the... 
Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare
A comprehensive study of the components of the delivery of modern-day cancer care in community oncology practices revealed that Medicare covers only 56% of the actual costs of administering chemotherapy and providing related infusion room services to seniors with cancer. The remaining costs — for essential services provided such as …  Read More →
Senator Slams FDA Advisory Committee’s Avastin Decision
Senator Slams FDA Advisory Committee’s Avastin Decision
Sen. Vitter has also called on HHS to remove the new U.S. Preventive Services Task Force breast cancer screening recs from the agency’s website.  Read More →
FDA to Review Bone Drugs After Studies Report Hip Breaks
FDA to Review Bone Drugs After Studies Report Hip Breaks
There have long been safety questions — and lawsuits — over whether bone-building drugs like Merck’s Fosamax can actually increase the chance of femur fractures. Today, the FDA said it was going to take another look at the safety issues. In a posting on its Web site, the FDA said a 2008 examination of data from makers of osteoporosis... 
What the New MS Drug Does (and What It Doesn’t Do)
What the New MS Drug Does (and What It Doesn’t Do)
The FDA just approved a new multiple sclerosis drug called Ampyra. The drug (also known as Fampridine-SR) helps some patients walk faster. Trouble walking is a serious problem for many MS patients. But only a minority of patients seem to benefit from Ampyra. In one study, 35% of people who took the drug showed improved walking speed, compared... 
Studies Cast a Starker Light on Depression Drugs
The value of using antidepressants to treat mild to moderate depression came under fire recently after a study in the Journal of the American Medical Association found that the drugs didn’t work much better than a placebo in those with mild to moderate depression. These findings were widely reported because with 164 million prescriptions written... 
  Related Tweets from Twitter
lavangiangel (lavangi angel)  : Heart Oxfordshire : Peru drugs pair await trial - Oxford Mail http://bit.ly/cDWHl5..
Updated : 2010-08-01T09:46:35Z   |  Reply  |  View Tweet
Drugs_Devices (Drugs and Devices OW)  : Some diabetes drugs linked to fractures - UPI.com: A U.S. researcher says post-menopausal women taking some diabet... http://bit.ly/9S4bg0..
Updated : 2010-08-01T09:46:33Z   |  Reply  |  View Tweet
Drugs_Devices (Drugs and Devices OW)  : HCV New Drugs: Veterans were exposed to unclean instruments at VA Hospital: HCV New Drugs: Veterans were exposed t... http://bit.ly/dnV7G9..
Updated : 2010-08-01T09:46:32Z   |  Reply  |  View Tweet
Drugs_Devices (Drugs and Devices OW)  : HCV New Drugs: Veterans were exposed to unclean instruments at VA Hospital: HCV New Drugs: Veterans were exposed t... http://bit.ly/dnV7G9..
Updated : 2010-08-01T09:46:32Z   |  Reply  |  View Tweet
MusicProMag (MusicPro Magazine)  : Twee pop vs guitar hero: If rock *n' roll is only about scoring drugs, groupies and ear-splitting noise, the Scott... http://bit.ly/deP4yU..
Updated : 2010-08-01T09:46:17Z   |  Reply  |  View Tweet
  Related News from Digg
No comments yet.

Spam Protection by WP-SpamFree

TOP